Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Clinical trial NCT01023880 · TERMINATED
Trial details
- NCT number
- NCT01023880
- Sponsor
- Cephalon
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-01-01
- Primary completion
- 2012-11-01
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.